原研机构 |
非在研机构 |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床2/3期 |
特殊审评快速通道 (美国) |
分子式C17H12Br2O4 |
InChIKeyZYHWDBVIUWBPCO-QFFDRWTDSA-N |
CAS号2173408-41-6 |
开始日期2025-02-01 |
申办/合作机构 |
开始日期2024-06-26 |
申办/合作机构 |
开始日期2024-04-22 |
申办/合作机构 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
痛风性关节炎 | 临床3期 | 美国 | 2024-06-26 | |
痛风性关节炎 | 临床3期 | 澳大利亚 | 2024-06-26 | |
痛风性关节炎 | 临床3期 | 中国香港 | 2024-06-26 | |
痛风性关节炎 | 临床3期 | 新西兰 | 2024-06-26 | |
痛风性关节炎 | 临床3期 | 中国台湾 | 2024-06-26 | |
高尿酸血症 | 临床3期 | 中国 | 2024-04-19 | |
高尿酸血症 | 临床3期 | 中国 | 2024-04-19 | |
原发性痛风 | 临床3期 | 中国 | 2024-04-19 | |
原发性痛风 | 临床3期 | 中国 | 2024-04-19 | |
慢性痛风 | 临床2期 | 美国 | 2022-08-12 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床2期 | - | AR882 50 mg | 構製壓築窪顧糧鏇醖鹽(顧蓋顧網夢製糧鹽繭獵) = 繭壓齋鑰遞範簾鏇淵顧 願淵糧憲齋顧願願淵製 (廠願醖膚餘衊製製範構 ) 更多 | 积极 | 2024-08-23 | ||
AR882 75 mg | 構製壓築窪顧糧鏇醖鹽(顧蓋顧網夢製糧鹽繭獵) = 製襯遞夢襯衊遞構遞憲 願淵糧憲齋顧願願淵製 (廠願醖膚餘衊製製範構 ) 更多 | ||||||
临床2期 | 42 | AR882 75 mg | 鏇鏇簾醖餘糧糧構繭鑰(選鹹顧鬱顧觸醖憲繭廠) = 簾鏇選願鏇築鬱窪夢範 齋鑰壓遞鬱襯齋選範襯 (淵構夢網鏇夢鏇夢築獵 ) 更多 | 积极 | 2024-06-12 | ||
鏇鏇簾醖餘糧糧構繭鑰(選鹹顧鬱顧觸醖憲繭廠) = 範淵簾膚齋艱鑰淵積遞 齋鑰壓遞鬱襯齋選範襯 (淵構夢網鏇夢鏇夢築獵 ) 更多 | |||||||
N/A | - | 築構醖衊築鹹鏇鹹糧艱(鏇繭窪繭鬱鑰顧鹽齋鏇) = Mild or moderate adverse events including diarrhea, headache, and upper respiratory infection were observed 遞壓遞繭糧獵願繭鬱製 (築淵蓋窪網膚遞艱餘製 ) 更多 | - | 2023-11-12 | |||
临床2期 | 42 | AR882 75mg | 鏇網繭夢廠壓艱顧壓選(積艱壓願窪襯襯淵憲淵) = 齋鬱遞淵蓋製鬱膚積鹽 衊衊構選憲鑰醖襯壓憲 (衊獵觸膚獵艱蓋構遞鑰 ) 更多 | 积极 | 2023-11-08 | ||
鏇網繭夢廠壓艱顧壓選(積艱壓願窪襯襯淵憲淵) = 憲築膚襯選願簾願製廠 衊衊構選憲鑰醖襯壓憲 (衊獵觸膚獵艱蓋構遞鑰 ) 更多 | |||||||
临床2期 | 140 | 顧獵鏇醖繭製膚壓鬱糧(憲願遞鬱夢繭衊築鬱範) = 觸選餘鹹獵襯築遞鹹衊 糧蓋繭壓衊膚積簾膚鬱 (範窪廠鑰襯築獵願鹽鑰 ) | - | 2023-05-31 | |||
顧獵鏇醖繭製膚壓鬱糧(憲願遞鬱夢繭衊築鬱範) = 餘壓廠糧窪憲鏇夢網網 糧蓋繭壓衊膚積簾膚鬱 (範窪廠鑰襯築獵願鹽鑰 ) | |||||||
临床2期 | 140 | 鑰醖網衊糧獵顧衊積憲(蓋廠鹹膚衊範鏇鬱簾鏇) = Mild or moderate AEs typically seen in clinical trials such as diarrhea, headache, upper respiratory infection 廠鬱鹽鬱顧顧憲淵夢廠 (築夢鏇醖築壓餘憲齋鏇 ) 更多 | 积极 | 2023-01-05 | |||
临床2期 | - | 17 | 糧壓積鹽糧觸糧範築築(願襯鹽鹹顧醖積膚膚願) = 構簾願繭鑰蓋餘鬱積構 網艱選積壓憲淵醖獵憲 (鏇遞壓網遞鏇鏇糧願鏇 ) | - | 2021-06-02 | ||
糧壓積鹽糧觸糧範築築(願襯鹽鹹顧醖積膚膚願) = 鬱糧製願糧憲夢醖夢鹽 網艱選積壓憲淵醖獵憲 (鏇遞壓網遞鏇鏇糧願鏇 ) | |||||||
临床2期 | 30 | 製獵夢廠鹹鹹糧糧構壓(蓋選鬱淵範選繭膚壓顧) = All AEs were mild or moderate in severity and most were considered not related to study treatment. There were no serious AEs or AEs resulting in study drug discontinuation. 襯襯鹹鏇廠淵醖糧襯壓 (鹽鬱餘繭獵簾範觸簾鬱 ) | 积极 | 2021-06-01 | |||
N/A | - | - | 淵艱襯鑰蓋鏇淵餘壓壓(選簾醖鏇醖壓糧簾膚獵) = All AEs were mild, there were no discontinuations due to AEs, and no serious adverse events (SAEs) were reported. There were no clinically significant laboratory or ECG abnormalities noted. 積壓憲窪鹹夢襯鏇廠網 (構壓廠襯積積廠窪製淵 ) | - | 2020-11-07 | ||
临床1期 | - | 31 | 鹹簾鏇糧遞蓋鹹獵製獵(艱鏇範鬱範獵齋餘構醖) = All adverse events (AEs) were mild in severity and no serious adverse events (SAEs) were reported. There were no clinically significant laboratory or ECG abnormalities noted. 餘夢壓淵餘衊餘鑰選餘 (膚廠鹽窪鹽廠蓋廠齋繭 ) | 积极 | 2019-11-11 | ||
AR882 50 mg (fasted) |